Stocks · Healthcare · Biotechnology
Krystal Biotech, Inc. KRYS
$322.28 -0.93% Close, Oct 2, 2026 · NASDAQ · Market cap $9.50B
High qualityLow risk
Next earnings report: Nov 2, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Diluted EPS over the last four quarters was $7.98, up 62.2% year over year.
- Over the past year the stock returned +79.4%, ahead of the S&P 500 by 64.4 percentage points.
- Earnings beat analyst estimates in each of the last 5 quarters (average surprise over the last four: +43.5%).
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 31%
- EPS growth (TTM, YoY)Top 23%
- FCF growth (TTM, YoY)Top 34%
- Revenue growth accelerationBottom 34%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 9%
- Gross marginTop 15%
- Operating marginTop 2%
- Cash conversion (OCF / net income)Bottom 27%
- Accruals (lower is better)Bottom 25%
- Net debt / EBITDA (lower is better)Top 14%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 22%
- Free-cash-flow yieldTop 27%
- EBITDA / enterprise valueTop 31%
- Sales / enterprise valueBottom 20%
- P/E vs own 5-year history (lower is better)Top 50%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 16%
- 6-month returnTop 36%
- 1-year return vs S&P 500Top 19%
- Distance from 52-week highTop 24%
- Trend checklist (0–4)Top 39%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 14%
- Consecutive EPS beatsTop 15%
- Share of analysts rating BuyTop 10%
- Upside to consensus price targetBottom 28%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 26%
- Maximum drawdown, 3 yearsTop 16%
- Beta vs S&P 500 (lower is better)Top 19%
- Net debt / EBITDA (lower is better)Top 14%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 25.1% | 22.6% | ↓ |
| EPS growth (YoY) | 79.8% | 62.2% | ↓ |
| Gross margin | 93.4% | 93.3% | ↓ |
| Operating margin | 38.8% | 44.9% | ↑ |
| FCF margin | 51.6% | 58.5% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 22.6% | 25.1% | ↓ | Top 31% |
| EPS growth (TTM, YoY) | 62.2% | 79.8% | ↓ | Top 23% |
| Gross margin | 93.3% | 93.4% | ↓ | Top 15% |
| Operating margin | 44.9% | 38.8% | ↑ | Top 2% |
| Net margin | 54.8% | 40.8% | ↑ | — |
| Free-cash-flow margin | 58.5% | 51.6% | ↑ | — |
| Return on invested capital | 14.4% | — | Top 9% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- 1.13×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -2.1%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 9.4%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +1.8 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- -1.92×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -0.25%
- Shareholder yield
- -0.25%
- Share count change, 1 year
- +3.1%
- Share count change, 3-year CAGR
- +4.8%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 3, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 5
- Beats in the last 8 reports
- 7 of 8
- Average EPS surprise, last 4
- +43.5%
- Average 2-day reaction, last 8
- -1.9%
- Positive 20 days after report
- 5 of 8
Analysts
- Consensus price target
- $395.20
- Target vs current price
- +22.6%
- Analysts with a rating
- 17
- Share rating Buy or Strong Buy
- 100%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 3, 2026 | +5.3% | -8.4% | -4.3% | +3.0% | — |
| May 4, 2026 | +26.2% | +7.9% | +14.9% | +12.1% | +36.6% |
| Feb 17, 2026 | +4.9% | +4.1% | -0.7% | -9.5% | +12.2% |
| Nov 3, 2025 | +137.5% | +0.2% | +0.2% | +8.9% | +41.4% |
| Aug 4, 2025 | +19.4% | -14.0% | -11.7% | -5.9% | +21.0% |
| May 6, 2025 | -13.0% | -14.1% | -14.1% | -19.3% | -5.2% |
| Feb 19, 2025 | +17.8% | +12.4% | +15.6% | +20.3% | -16.1% |
| Nov 4, 2024 | +1.1% | -3.1% | +13.2% | +10.5% | -9.4% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 3, 2026 | $1.79 | $1.70 | +5.3% | $119.2M |
| May 4, 2026 | $1.83 | $1.45 | +26.2% | $116.4M |
| Feb 17, 2026 | $1.70 | $1.62 | +4.9% | $107.1M |
| Nov 3, 2025 | $2.66 | $1.12 | +137.5% | $97.8M |
| Aug 4, 2025 | $1.29 | $1.08 | +19.4% | $96.0M |
| May 6, 2025 | $1.20 | $1.38 | -13.0% | $88.2M |
| Feb 19, 2025 | $1.52 | $1.29 | +17.8% | $91.1M |
| Nov 4, 2024 | $0.91 | $0.90 | +1.1% | $83.8M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 40.4× | 42.0× | 45th | Top 22% |
| P/E (forward) | 42.4× | — | — | — |
| EV / EBITDA | 41.6× | — | — | Top 31% |
| EV / Sales | 20.62× | — | — | Bottom 20% |
| Free-cash-flow yield | 2.71% | — | — | Top 27% |
| Earnings yield | 2.48% | — | — | Top 22% |
P/E over the past five years
Range 27.4× – 96.5× since Mar 31, 2024. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
What moved the stock over the past year
- Price return, 1 year
- +79.4%
- Earnings per share growth (TTM)
- +62.2%
- Change in P/E multiple
- +42.8%
Most of the move came from earnings growth.
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 262
- 50-day average slope (20 days)
- -2.1%
- 200-day average slope (20 days)
- +4.1%
- Distance from 50-day average
- -5.9%
- Distance from 200-day average
- +6.9%
- RSI (14)
- 36.6
- Relative volume
- 1.52×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 42.8%
- Volatility vs own 5-year history
- 32th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.58
- Correlation with S&P 500
- 0.20
- Current drawdown from 1-year high
- -14.8%
- Maximum drawdown, 3 years
- -42.3%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Mar 1, 2021 | Nov 26, 2021 | -53.4% | 189 days | 1 days (Nov 29, 2021) |
| Nov 29, 2021 | May 11, 2022 | -44.5% | 113 days | 231 days (Apr 13, 2023) |
| Jul 26, 2024 | May 28, 2025 | -42.3% | 209 days | 125 days (Nov 24, 2025) |
| Jun 13, 2023 | Nov 9, 2023 | -26.3% | 104 days | 48 days (Jan 22, 2024) |
| Oct 12, 2020 | Nov 6, 2020 | -21.6% | 19 days | 15 days (Nov 30, 2020) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $9.50B
- P/E (TTM)
- 40.4
- EPS, diluted (TTM)
- $7.98
- Revenue (TTM)
- $440.5M
- 52-week range
- $178.61 – $382.54
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $50.7M | $290.5M | $389.1M |
| Gross profit | $0 | $0 | $47.6M | $270.5M | $360.4M |
| Operating income | -$68.3M | -$145.2M | -$109.7M | $65.7M | $161.3M |
| Net income | -$69.6M | -$140.0M | $10.9M | $89.2M | $204.8M |
| EPS (diluted) | -$3.13 | -$5.49 | $0.39 | $3.00 | $6.84 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $83.8M | $91.1M | $88.2M | $96.0M | $97.8M | $107.1M | $116.4M | $119.2M |
| Net income | $27.2M | $45.5M | $35.7M | $38.3M | $79.4M | $51.4M | $55.9M | $54.8M |
| EPS (diluted) | $0.91 | $1.52 | $1.20 | $1.29 | $2.66 | $1.70 | $1.83 | $1.79 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$47.9M | -$100.6M | -$88.8M | $123.4M | $200.9M |
| Capital expenditure | -$68.3M | -$53.0M | -$11.8M | -$4.2M | -$12.0M |
| Free cash flow | -$116.3M | -$153.5M | -$100.6M | $119.2M | $188.9M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $355.6M | $36.0M | $203.5M | $32.4M | $22.7M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $845.6M
- Total assets
- $1.50B
- Total liabilities
- $141.5M
- Total debt
- $8.9M
- Net debt
- -$418.9M
- Shareholders’ equity
- $1.36B
As of Jun 30, 2026 (filed Aug 3, 2026).
Short interest
- Shares sold short
- 3,163,642
- Days to cover
- 13.23
- Change vs previous report
- -5.5%
FINRA short interest, settlement date Sep 15, 2026.